What Abbvie Contract Manufacturing does

AbbVie Contract Manufacturing (also known as AbbVie CMO) is the contract manufacturing operations division of AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company headquartered in North Chicago, Illinois. The division operates as an embedded contract manufacturing organization (CMO), offering third-party pharmaceutical and biotech clients access to the manufacturing infrastructure, technical expertise, and regulatory capabilities originally developed for AbbVie's own commercial drug portfolio. With over 40 years of experience safeguarding client intellectual property and patient supply, AbbVie CMO serves clients across the full drug lifecycle from early clinical development through commercial-scale production.

The division's service portfolio spans drug substance and drug product manufacturing across small molecules, large molecules (biologics), and advanced modalities. Core technical capabilities include antibody drug conjugate (ADC) manufacturing with global monoclonal antibody capacity exceeding 85,000 liters at cGMP scale from 1,000 L to 12,000 L bioreactors, hot melt extrusion (HME) with the largest network of pharmaceutical twin-screw extruders globally, aseptic fill/finish for vials and prefilled syringes, oral solid dose manufacturing with potent compound handling down to less than 1 microgram per cubic meter, HPAPI manufacturing up to OEB 5 containment, and lyophilization. The 2024 acquisition of Immunogen further strengthened ADC capabilities. Operations span 12 manufacturing facilities across the United States (North Chicago, Worcester, Waco), Puerto Rico (Barceloneta), Germany (Ludwigshafen), Italy (Campoverde), Ireland (Cork, Clonshaugh, Westport, Sligo), and France (Pringy).

Revenue is generated through professional services contracts for contract development and manufacturing, with custom project-based pricing determined by manufacturing scale, product type, development phase, and service scope, typically structured as multi-year agreements. The go-to-market is enterprise field sales targeting pharmaceutical and biotech companies through dedicated business development teams, supported by content marketing, industry conference presence, and direct engagement channels. The embedded CMO model differentiates from stand-alone CDMOs by leveraging AbbVie's financial backing, eliminating capacity-filling dependency, and providing up-to-date knowledge of global regulatory requirements derived from the parent's own product registrations worldwide. The division has won the CMO Leadership Award from Life Science Leader every year since the award category's inception in 2013.

Name

Abbvie Contract Manufacturing

Legal name

AbbVie Inc.

Website

https://abbviecontractmfg.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

AbbVie Contract Manufacturing is the embedded CMO division of AbbVie Inc., offering pharmaceutical and biotech clients contract development and manufacturing services for small molecules, biologics, ADCs, and drug products across 12 global facilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Contract manufacturing services
• Biologics manufacturing
• Antibody drug conjugates
• Hot melt extrusion
• Aseptic fill finish

Headquarters

HQ city

North Chicago

HQ country

United States

HQ region

North America

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: AbbVie CMO provides contract development and manufacturing services to pharmaceutical and biotech companies. Revenue is generated through service contracts for drug substance and drug product manufacturing across clinical and commercial phases. The embedded CMO model allows them to offer services from early development through commercialization.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

AbbVie Contract Manufacturing is an embedded contract manufacturing organization (CMO) that provides drug substance and drug product contract development and manufacturing services to pharmaceutical and biotech companies. Services span small molecule API, large molecule (biologics/mAbs), antibody drug conjugates (ADC), hot melt extrusion, oral solid dose, aseptic fill finish, prefilled syringes, eye care, and HPAPI, delivered across 12 manufacturing sites in the US and Europe from clinical development through commercial supply.

Product overview

AbbVie Contract Manufacturing operates as an embedded CMO (Contract Manufacturing Organization) offering a comprehensive portfolio of pharmaceutical development and manufacturing services spanning both drug substance and drug product. The service portfolio includes Antibody Drug Conjugates (ADC), Aseptic Fill Finish, Biologics (mAbs), Custom API, Eye Care, Hot Melt Extrusion (HME), HPAPI, Large Molecule Manufacturing, Oral Solid Dose, Prefilled Syringes, and Small Molecule Manufacturing. Services range from early clinical development through commercial-scale production, supported by a global network of 12 facilities across the US and Europe. The embedded CMO model leverages AbbVie's own pharmaceutical expertise and facilities, enabling partners to access capabilities from API synthesis through final drug product packaging within a single network.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody Drug Conjugates (ADC) Targeted therapeutic manufacturing combining monoclonal antibodies with active pharmaceutical ingredients via linker-payload conjugation, enabling precise cancer cell delivery for pharmaceutical and biotech clients.
• Aseptic Fill Finish High-quality biologic drug product fill-finish manufacturing for vials, syringes, and cartridges under strict aseptic conditions, for pharmaceutical and biotech clients.
• Biologics (mAbs & mAb derivatives) Monoclonal antibody and derivative manufacturing service leveraging over 85,000 L of bioreactor capacity at cGMP scale from 1,000 L to 12,000 L for pharmaceutical and biotech clients.
• Custom API Complex chemical API synthesis and manufacturing at scale, including microbial fermentation, catalysis, and distillation techniques, for pharmaceutical clients.
• Eye Care Ophthalmic drug product manufacturing including sterile eye ointments, unit-dose and multi-dose formulations with precise dosing capabilities for pharmaceutical clients.
• Hot Melt Extrusion (HME) Proprietary bioavailability enhancement technology using twin-screw extruders to create amorphous solid dispersions for poorly soluble APIs, available in both the US and Europe for pharmaceutical clients.
• HPAPI (Highly Potent Active Pharmaceutical Ingredient) Manufacturing of highly potent compounds up to OEB 5 containment levels, from drug substance through finished drug product at a single location, for pharmaceutical clients.
• Large Molecule Manufacturing End-to-end large molecule/bulk drug substance production including cell culture, chromatography, purification, and downstream processing for pharmaceutical and biotech clients.
• Oral Solid Dose Tablet and capsule manufacturing spanning granulation, compression, coating, and encapsulation capabilities across multiple global facilities for pharmaceutical clients.
• Prefilled Syringes for Medical Devices Syringe filling and medical device assembly including compounding, heat/steam terminal sterilization, automated visual inspection, and full QC release testing for pharmaceutical clients.
• Small Molecule Manufacturing Chemical synthesis-based API and oral solid dose drug product manufacturing for small molecules across global facilities for pharmaceutical clients.

Quantifiable outcome

• 12-time CMO Leadership Award Winner
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• ImmunogencoreStrategic or Co-development PartnerAbbVie acquired Immunogen and gained access to their ADC technology and commercial product. Immunogen brought ADC expertise and one commercial product to AbbVie's portfolio, strengthening their position in the antibody drug conjugate space.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lonza Group: Lonza is the world's largest CDMO offering small molecule API, biologics (mammalian and microbial), cell and gene therapy, and drug product services across a global network. It is a direct peer to AbbVie CMO given overlapping capabilities in commercial API manufacturing, biologics drug substance, and integrated small-molecule/large-molecule offerings serving similar pharmaceutical and biotech customers.
• Catalent: Catalent is a major global CDMO offering biologics, oral and inhaled drug product, and cell and gene therapy services, with significant prefilled syringe and softgel capabilities overlapping AbbVie CMO's aseptic fill finish and OSD offerings. Acquired by Novo Holdings in 2024, Catalent competes head-to-head with AbbVie CMO for commercial-scale pharma manufacturing contracts across similar modalities.
• Aenova Group: Aenova is a leading European CDMO offering solid dosage forms, sterile liquids, and API manufacturing across multiple sites. It directly competes with AbbVie CMO for oral solid dose, aseptic fill finish, and small molecule contract manufacturing contracts serving similar pharma customers across Europe and the US.
• WuXi Biologics: WuXi Biologics is one of the largest biologics CDMOs globally, providing end-to-end monoclonal antibody and bispecific development, manufacturing, and conjugation services. It directly competes with AbbVie CMO in mAb drug substance, ADC manufacturing, and biologics fill finish, serving the same biotech and pharma client base seeking outsourced mammalian cell culture capacity.
• Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth Biotechnologies is a major biologics CDMO offering microbial and mammalian cell culture, with significant recent capacity expansions in the US and UK. It competes directly with AbbVie CMO for biologics drug substance and fill finish contracts targeting pharma and biotech clients advancing complex biologics and ADCs.
• Recipharm: Recipharm is a European-headquartered CDMO offering small molecule API, OSD, sterile injectables, and inhalation services. It competes directly with AbbVie CMO for pharmaceutical contract manufacturing contracts, particularly in biologics fill finish and small molecule drug product, with overlapping client rosters in branded pharma.
• Samsung Biologics: Samsung Biologics is a leading biologics CDMO with very large-scale mammalian cell culture capacity, providing drug substance, aseptic fill finish, and bioservices. It directly competes with AbbVie CMO for monoclonal antibody manufacturing contracts at commercial scale, with comparable cGMP bioreactor offerings and a rapidly expanding ADC and biosimilar services portfolio.
• Siegfried Holding: Siegfried is a Swiss-listed CDMO specializing in small molecule API and drug product manufacturing, including HPAPI, OSD, and sterile fill finish. It directly competes with AbbVie CMO for small molecule commercial manufacturing contracts, particularly in highly potent compounds and integrated API-to-drug-product offerings targeting branded pharmaceutical clients.
• Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's BioXcellence is the company's contract biopharmaceuticals business, offering mammalian and microbial cell culture, viral vector, and biopharmaceutical fill finish services. It competes directly with AbbVie CMO for biologics manufacturing contracts, particularly in monoclonal antibodies, recombinant proteins, and ADC-related modalities, serving a similar pharma and biotech customer base.

Broad incumbents

• Thermo Fisher Scientific (CDMO / Patheon): Thermo Fisher Scientific operates a large pharmaceutical services business (formerly Patheon) covering small molecule API, OSD, sterile fill finish, and biologics services as part of a broader life sciences portfolio. As a broad incumbent it overlaps with AbbVie CMO across most service lines but competes as one of many divisions within a much larger tools, diagnostics, and clinical services enterprise.

Market position

Weaknesses4 records

Competitive moat7 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/abbvieCM
• YouTubeyoutube.com/channel/UCn1kWwh7rdaBopwtLp1pm5A
• LinkedInlinkedin.com/showcase/abbvie-contract-manufacturing

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abbvie Contract Manufacturing